Background: The myocardin-related transcription factor (MRTF) family interacts with globular (G) actin in the cytoplasm. Following actin polymerization in response to Rho-GTPase signalling, downstream of mechanical stress or growth factor signalling, MRTFs translocate into the nucleus to activate gene transcription of muscle specific genes such as alpha-smooth muscle actin (aSMA) and fibrotic genes such as CTGF through an interaction with the serum response factor (SRF) on CArG box regulatory elements [CC(A/T) 6 GG] . MRTF-A transactivated collagen gene transcription through a Sp1/SRF recruitment, far more than other members of the myocardin family. MRTFA is implicated in differentiation to myofibroblasts by multiple cell lineages, epithelial (EMT), endothelial (EnMT), or smooth muscle cells to synthetic mesenchymal myofibroblast like cells. We hypothesized that MRTFA is necessary for wound healing and is a point of convergence for pro-fibrotic mechanisms in SSc. Methods: MRTF-A knockout (KO) and wild type (WT) control mice were subjected to excisional wounding (4 mm punch biopsy, basal wound area 12.6 mm 2 ). MRTF-A signal transduction was studied in healthy control and SSc fibroblasts cultured on reduced mechanical stress collagen gels (Softwell 0.5 kPa). The small molecule inhibitor CCG1423 was used to antagonize MRTF-A signalling. SSc fibrosis responses were modelled by collagen gel contraction, CTGF, and type I collagen synthesis. MRTF-A signalling was assayed by Western blotting of nuclear and cytoplasmic extracts. Results: Following excisional wounding MRTF-A KO mice wounds failed to close normally and increased in size during days 1-7, wound area decreasing by day 11. When compared with wild type controls, MRTF-A KO wounds were enlarged at day 7 (WT area 6 mm 2 , KO area 12.4 mm 2 , P < 0.03), and day 11 (WT area 0.42 mm 2 , KO area 3.4 mm 2 , P < 0.01). The histology of Day 11 skin wounds showing reduced scar formation and abnormal vessels, which were dilated, and exhibited extravasation of red blood cells. Gel contraction by WT fibroblasts was enhanced by TGFb and blocked by CCG1423 1 mM (basal conditions mean gel mass 0.176 g, TGFb treated 0.118 g, TGFb þ CCG1423 0.238g, P < 0.002). Dermal fibroblasts from MRTF-A KO mice showed reduced basal gel contraction, and impaired response to TGFb,(basal conditions mean gel mass 0.349 g, TGFb treated 0.259 g, TGFb þ CCG1423 0.313 g (P < 0.05 basal vs wild type). SSc fibroblasts showed enhanced basal CTGF and type I collagen which was suppressed to normal levels by CCG-1423. On soft tissue culture substrates SSc fibroblasts but not control fibroblasts showed constitutive nuclear localization of MRTF-A, enhanced by TGFb. Conclusion: MRTF-A has a role in wound contraction and in new vessel formation during tissue repair. MRTF-A signalling is altered in SSc fibroblasts, present under basal conditions. Increased synthesis of pro-fibrotic proteins by SSc fibroblasts is dependent on the MRTF-A pathway. CCG1423 and its derivatives may be potential anti-fibrotics to benefit SSc fibrosis. In addition we examine correlation between SCF levels and severity of pruritus and increased skin pigmentation.
Methods: Blister fluid, tissue and plasma samples were harvested from healthy controls and SSc patients. Collation of data including pruritus and pigmentation scores was also obtained. Migration was assessed using the scratch wound assay and transwell migration. The expression and quantity of SCF and c-Kit in SSc and control plasma, blister fluid, and conditioned media was assessed by ELISA. Results: SCF expression was enhanced in SSc epidermis samples by qPCR (566 vs 336 corrected copy numbers respectively). Transwell migration showed dose dependent response for rSCF with 350 migrating SSc lung fibroblasts at a concentration of 100 ng/ml, 315 cells at 10 ng/ml, 307 cells at 5 ng/ml, 241 cells at 2.5 ng/ml, 234 cells for negative control and 336 cells for positive control (PDGF-BB 10 ng/ml) after 4 hours incubation, suggesting that SCF acts as a chemoattractant. In contrast, ELISA data showed a decrease of soluble c-kit expression in plasma of SSc patients compared with healthy controls (13.9 ng/ml and 19.6 ng/ml respectively P ¼ 0.03), whereas plasma SCF expression was not significantly altered in SSc (1221.2 pg/ml SSc and 1325 pg/ml for healthy control P ¼ 0.36). In addition, a reduction was observed of SCF levels in SSc blister fluids compared with healthy controls (1223 pg/ml and 1414 pg/ml, P ¼ 0.29, while in fibroblast conditioned media, SCF showed a trend to be increased (152 pg/ml) compared with controls (130 pg/ml) P ¼ 0.002. Conclusion: Although SCF mRNA is elevated in the epidermis of SSc subjects, there was no significant difference in the level of SCF protein or soluble c-kit in plasma, or blister fluid. If SCF/c-Kit expression is directly related to disease activity, studying a subgroup with untreated active disease may be more definitive. There is evidence that SCF is being released by SSc fibroblasts and is capable of promoting migration of these cells. Further work is required to elucidate the potential role of SCF in pathogenesis and its ability to drive pruritus, a neglected but important symptom of this challenging disease. Disclosure statement: The authors have declared no conflicts of interest. Background: Clinical diversity in SScis likely to reflect multifaceted pathogenesis and the effect of key growth factors or cytokines operating within a disease-specific microenvironment. Dermal interstitial fluid sampling offers the potential to examine local biological mechanisms and define protein expression within lesional tissue. We have used multiplex cytokine analysis to define the inflammatory and immune activity in the lesions of SSc patients. Methods: Interstitial fluid samples from the forearm skin of patients (n ¼ 25; DcSSc ¼ 19; LcSSc ¼ 6) or healthy controls (HC) (n ¼ 10) were collected using a dermal suction blister method, together with contemporaneous serum samples. Both the serum and interstitial fluid samples were profiled by Luminex array for inflammatory cytokines, chemokines, and growth factors. Permutation analysis was used to compare cytokine levels in SSc and HC samples, as well as to compare the difference between serum samples and healthy control samples. Pearson's correlation coefficient was used to assess any correlation between serum and interstitial fluid samples within the patient samples.
MULTIPLEX CYTOKINE ANALYSIS OF DERMAL INTERSTITIAL BLISTER FLUID IN SYSTEMIC SCLEROSIS DEFINES POTENTIAL PATHOGENIC PATHWAYS AND DIFFERENTIATES CLINICAL SUBSETS
Results: Luminex array profiling of the dermal blister fluid showed increased inflammatory cytokines (mean IL-6 in SSc-77.2 pg/ml, HC-17.8 pg/ml, P ¼ 0.009, mean IL-17 in SSc-0.61 pg/ml, HC-0 pg/ml, P ¼ 0.03),and vascular growth factors (VEGF21.7 pg/ml in SSc, HC-13.5 pg/ml (P ¼ 0.26), PDGF-aa 16.4 pg/ml in SSc, HC-0.97 pg/ml, P ¼ 0.049). Additionally MCP-3(CCL7), IL-15 and IFN-g were all significantly increased in SSc compared with HC (P < 0.05). Within the serum, Luminex array profiling highlighted a significant increase in mean IL-12p40 (SSc-31.7 pg/ml, HC-2.05 pg/ml, P ¼ 0.012) and mean IL-1a (SSc-21.15 pg/ml, HC-2.25 pg/ml, P ¼ 0.029) in SSc compared with controls. There was no significant difference for other cytokines.
Comparing the luminex array profiling of the dermal blister fluid from those with SSc, with the paired serum samples, the only significant correlation was in MCP-3 (r 2 ¼ 0.31, P ¼ 0.013). Other proinflammatory cytokines [IL-6 (r 2 ¼ 0.083, P ¼ 0.23), IL-17 (r 2 ¼ 0.02, P ¼ 0.56)] and growth factors [VEGF (r 2 ¼ 0.03, P ¼ 0.47), PDGF (r 2 ¼ 0.08, P ¼ 0.22)] showed no correlation between serum samples and dermal blister fluid. Interestingly, the healthy controls showed greater correlation between the Luminex array results from the dermal blister fluid and serum samples, with many reaching significance (IL-10, MCP-3, IL1ra, FGF-2). Conclusion: Our results confirm the potential utility of dermal blister fluid to define local biological processes in SSc, and identifies profibrotic, angiogenic and T-cell derived factors expressed locally within the skin lesions. In contrast, analysis plasma samples revealed elevation of monocyte derived inflammatory proteins. Absence of correlation between the interstitial fluid samples and paired serum samples suggests that the dermal blister sampling method reflects local dermal protein expression rather than exudates from the plasma into the skin. This dermal suction method offers an opportunity to profile the local inflammatory process occurring within the skin and has potential to complement clinical and gene expression based classification to facilitate targeted therapy, as well as providing potential markers of disease activity or treatment effect. Disclosure statement: The authors have declared no conflicts of interest. Background: Scleroderma renal pathology is predominantly vascular and fibrotic without major inflammatory features when compared with other autoimmune rheumatic diseases. Accelerated hypertension and rapidly progressive renal dysfunction are hallmarks of scleroderma renal crisis. No current animal model of scleroderma (SSc) develops this complication. The TbRIIÁk-fib transgenic mouse model of SSc has a systemic vascular phenotype comprising hypertension and large vessel adventitial fibrosis without constitutive renal disease. However, the response to long-term further elevation of blood pressure or an inflammatory or toxic renal insult has not been studied. We have therefore explored the link between altered TGFb bioactivity, vasospasm and inflammatory stress on the systemic vascular endothelium using 3 renal injury models: nitric oxide synthase inhibition; nephrotoxic nephritis and ciclosporin toxicity in this strain. Methods: Histological assessment of cardiac and renal architecture, immunostaining for inflammatory cells and assessment of murine serum and urine were performed on adult male transgenic (TG) and littermate wildtype (WT) animals (n ¼ 6) treated with either the NO synthase inhibitor L-NAME for 20 weeks, a single dose of nephrotoxic serum with pre-immunization or ciclosporin 30 mg/kg/day for 4 weeks. Biochemical analysis of the TGFb signalling pathway was performed assessing RNA and protein using whole organ isolates, and by immunostaining of tissue sections. Results were compared with appropriate TG and WT control groups. Results: Increased cardiac mass and collagen measured by both qPCR and Sircol assay in TG and WT treated groups demonstrated that L-NAME treatment successfully induced hypertensive stress in this strain. Whole kidney lysates from L-NAME treated TG animals showed upregulated expression of Col1a1 (TG untreated copy number 3937 AE 315, TG treated 6319 AE 48, P < 0.05) and Pai-1 (TG untreated 410 AE 57, TG treated 740 AE 74, P < 0.05), and glomerulosclerosis was present on sirius red staining in the TG treated group, suggesting that these animals exhibited an enhanced renal fibrotic response when compared with WT treated animals. No other structural vascular changes were identified. In contrast, by day 14, TG animals had developed significantly less proteinuria following treatment with Background: Nail-fold capillaroscopy (NFC) patterns of vasculopathy have been well described in SSc but few studies have reported abnormalities in an unselected cohort of patients with RP/across the rheumatic conditions in a real-life clinical setting. Our objectives were to report NFC findings in patients with RP and describe the association with clinical diagnosis and serological profile. Methods: We evaluated patients with primary and secondary RP (pRP or sRP respectively) attending the Leeds Teaching Hospitals NHS Trust rheumatology clinics that were referred for and underwent light/ video-NFC. Prospective documentation included clinical diagnosis, antibody (Ab) status and capillaroscopy findings. Patients were categorized: Ab negative (-ve) pRP, Ab positive (þve) sRP, SScrelated sRP and other CTD-related (non-SSc) sRP. NFC patterns were determined: normal, non-specific, early, active or late SSc patterns. Results: 347 patients were referred to the NFC service between January 2009 and October 2013. Of these, 293 were determined to have true RP (241 (82%) female and mean (S.D.) age 48 (15) years). 193 (66%) were Abþve. 190 (65%) were ANAþve (49 (26%) ACAþve, 11 (6%) Scl70þve and 21 (11%) RNPþve). 79 (27%) had Ab-ve pRP, 99 (34%) Abþve sRP, 49 (17%) SSc-related sRP (4 Ab-ve), and 66 (23%) other (non-SSc) CTD-related sRP (17 Ab-ve). Of the latter, 35 (53%) had UCTD, 14 (21%) inflammatory arthritis, 6 (9%) MCTD, 4 (6%) SLE and 6 (9%) other autoimmune conditions. 11 with sRP had history of digital ulceration (DU). Non-specific abnormalities, and to a lesser extent early patterns, were seen across all diagnoses (Table 1) . Analysing those with sRP, greater active and late patterns were seen in SSc-related sRP than in those without SSc (Abþve sRP or CTDrelated (non-SSc) sRP) (active: 39% vs 7% respectively, relative risk
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